Magenta Therapeutics

December 06, 2018

Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting

Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.

November 21, 2018

Ash 2018 preview – smaller groups get their turn in the spotlight

Swedish Orphan Biovitrum made waves yesterday by getting its rare disease asset emapalumab into the Ash late-breakers – and bagging approval soon afterwards.

July 02, 2018

June rush drives near-record quarter for biotech flotations

Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.

Magenta Therapeutics

Ash 2018 event analyzer – Losers edge out winners in year’s final major meeting

Ash 2018 preview – smaller groups get their turn in the spotlight

June rush drives near-record quarter for biotech flotations

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

Evaluate Vantage 2021 Preview

Editor's Picks

2020 wins top of the froths for biotech stocks

Biotech flotations remain in high demand

Glaxo’s growth problem

Go or no go? Oncology decisions ahead for the FDA

Pfizer reveals its PD-1 secret